NANOBIOTIX (NANO.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:NANO - FR0011341205 - Common Stock
NANO.PA Key Statistics, Chart & Performance
The current stock price of NANO.PA is 18 EUR. In the past month the price decreased by -10.67%. In the past year, price increased by 468.23%.
NANO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.57 | 42.91B | ||
| 1AE.DE | ARGENX SE | 63.14 | 41.33B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.16B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.11B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.99B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.88B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 929.30M | ||
| 6IV.DE | INVENTIVA SA | N/A | 834.75M | ||
| PHIL.MI | PHILOGEN SPA | 19.56 | 652.05M | ||
| FYB.DE | FORMYCON AG | N/A | 459.42M |
Related stock screener links
About NANO.PA
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
NANOBIOTIX
60 rue de Wattignies
Paris ILE-DE-FRANCE FR
Employees: 108
Phone: 33140260470
NANOBIOTIX / NANO.PA FAQ
What does NANO do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
What is the current price of NANO stock?
The current stock price of NANO.PA is 18 EUR. The price increased by 4.41% in the last trading session.
Does NANO stock pay dividends?
NANO.PA does not pay a dividend.
What is the ChartMill rating of NANOBIOTIX stock?
NANO.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is NANO.PA stock listed?
NANO.PA stock is listed on the Euronext Paris exchange.
What is the expected growth for NANO stock?
The Revenue of NANOBIOTIX (NANO.PA) is expected to grow by 24.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for NANOBIOTIX?
NANOBIOTIX (NANO.PA) currently has 108 employees.
NANO.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NANO.PA. When comparing the yearly performance of all stocks, NANO.PA is one of the better performing stocks in the market, outperforming 99.48% of all stocks.
NANO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. Both the profitability and financial health of NANO.PA have multiple concerns.
NANO.PA Financial Highlights
Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -47.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NANO.PA Forecast & Estimates
12 analysts have analysed NANO.PA and the average price target is 21.95 EUR. This implies a price increase of 21.93% is expected in the next year compared to the current price of 18.
For the next year, analysts expect an EPS growth of 55.91% and a revenue growth 24.15% for NANO.PA